Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis
JAMA Nov 17, 2021
Aminian A, Al-Kurd A, Wilson R, et al. - Researchers aimed at determining if bariatric surgery could aid in lowering the incidence of major adverse liver outcomes and major adverse cardiovascular events (MACE) in patients with obesity and biopsy-proven fibrotic nonalcoholic steatohepatitis (NASH) without cirrhosis.
In the SPLENDOR (Surgical Procedures and Long-term Effectiveness in NASH Disease and Obesity Risk) study, researchers identified a total of 1,158 adult patients with obesity who fulfilled enrollment criteria for this study, including confirmed histological diagnosis of NASH and presence of liver fibrosis (histological stages 1-3).
Of these patients, 650 patients underwent bariatric surgery (Roux-en-Y gastric bypass, sleeve gastrectomy) and 508 patients received nonsurgical care.
Outcomes revealed a significant correlation of undergoing bariatric surgery with a lower risk of major adverse liver outcomes (adjusted absolute 10-year risk difference of 12.4%) and major adverse cardiovascular events (adjusted absolute 10-year risk difference of 13.9%).
Exclusive Write-ups & Webinars by KOLs
Daily Quiz by specialty
Paid Market Research Surveys
Case discussions, News & Journals' summaries